Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Humanized and Charge-Optimized CSPG4-Specific CAR-T Cells Show Enhanced Efficacy Against Head and Neck Squamous Cell Carcinoma

ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy for head and neck squamous cell carcinoma (HNSCC) is hampered by the lack of a robust tumor antigen and a suitable CAR design.CSPG4 is highly expressed in HNSCC clinical samples and cell lines, correlating with poor prognosis. Its knockout markedly reduced tumor cell proliferation in vitro and in vivo, validating CSPG4 as an attractive CAR target. First‑generation CSPG4.CAR‑T cells bearing the murine scFv 763.74 showed potent in vitro cytotoxicity but failed to control tumor growth in vivo due to excessive tonic signaling and early exhaustion. By humanizing the scFv framework to reduce positive_x001E_charge residues and immunogenicity, we generated CAR_x001E_T cells with low tonic signaling, diminished exhaustion and differentiation, enhanced tumor_x001E_specific killing, and prolonged in vivo persistence, resulting in superior antitumor activity in both xenograft and PDX models.

ORGANISM(S): Homo sapiens

PROVIDER: GSE315646 | GEO | 2026/01/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The role of Ng2/Cspg4 in soft tissues sarcoma

Project description:NG2/CSPG4 is expressed in soft tissue sarcomas, however, its function in this tumor type, and its capacity to serve as a therapeutic target are unknown. Here, we used genetically engineered mice and cells from human tumors to determine the function of Ng2/Cspg4 in soft tissue sarcoma initiation and growth. We also investigated the potential for NG2/CSPG4 mAb immunotherapy to target human sarcomas established as xenografts in mice. Inhibiting Ng2/Cspg4 expression in established soft tissue sarcomas is associated with a smaller tumor volume and a reduction in cell proliferation. Intriguingly, deleting Ng2/Cspg4 at the time of tumor initiation has the opposite effect. Gene profiling found that Igfbp3/5 are substantially downregulated when Ng2/Cspg4 is depleted at the time of tumor initiation, but upregulated or only minimally downregulated when Ng2/Cspg4 is depleted after tumor initiation. Furthermore, the normal regulation of Igfbp is blunted when Ng2/Cspg4 is deleted at the time of tumor initiation. Our data show a difference in NG2/CSPG4 function in tumor initiation and maintenance, and provides pre-clinical evidence supporting NG2/CSPG4 as a therapeutic approach in soft tissue sarcoma.

2017-04-07 | GSE97489 | GEO

A Tonic Signaling Code Governs CAR-T Cell Efficacy in Diffuse Midline Glioma

Project description:Diffuse midline glioma (DIPG/DMG) is a uniformly fatal pediatric brain tumor. While CAR T-cell therapy holds promise, clinical responses remain inconsistent, largely due to limited CAR-T persistence and premature exhaustion. Reliable biomarkers to predict therapeutic efficacy are lacking, and proposed T-cell exhaustion or stemness markers offer limited predictive value. Here, we systematically evaluate CAR-T cells against the clinically relevant tumor antigen B7-H3 and identify tonic signaling, antigen-independent CAR activation, as a key determinant of therapeutic performance. B7-H3 CAR-T cells with minimal tonic signaling show superior tumor killing, persistence, and resistance to exhaustion in patient-derived DIPG models. Integrative single-cell and multi-omic profiling identifies a tonic signaling–associated gene signature that consistently outperforms conventional exhaustion or stemness markers in predicting CAR-T efficacy across multiple independent clinical trial datasets, including DIPG/DMG and other tumor types. Thus, our findings establish a mechanistic and predictive framework to guide CAR design and improve clinical outcomes.

2025-12-04 | GSE305987 | GEO

Tonic Signaling Shaped by Epitope Targeting Governs CAR-T Cell Fitness and Antitumor Activity in Diffuse Midline Glioma [RNA-Seq]

Project description:We systematically evaluated B7-H3–targeting CAR-T cells derived from three monoclonal antibodies (376.96, MGA271, and Hu8H9) in diffuse midline glioma (DMG or DIPG), a fatal pediatric brain tumor. Among these, 376.96 CAR-T cells had markedly lower tonic signaling, diminished expression of exhaustion markers, and enhanced tumor killing, cytokine production, and persistence. Transcriptomic and epigenomic profiling revealed a restrained activation state with reduced tonic signaling pathways and elevated stemness properties, oxidative metabolism, and innate immune sensing in these cells. In patient-derived spheroids and orthotopic DIPG xenografts, mRNA-based 376.96 CAR-T cells achieved robust tumor control and extended survival. By leveraging epitope selection, we reveal a mechanistic link between tonic signaling and CAR-T cell exhaustion, and provide a rational framework for optimizing CAR-T cell design to achieve improved efficacy and durability in pediatric brain tumor therapy.

2025-12-04 | GSE302514 | GEO

Tonic Signaling Shaped by Epitope Targeting Governs CAR-T Cell Fitness and Antitumor Activity in Diffuse Midline Glioma [CUT&Tag]

2025-12-04 | GSE302513 | GEO

NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis

Project description:Changes in the mechanical homeostasis of the temporomandibular joint (TMJ) can lead to the initiation and progression of degenerative arthropathies such as osteoarthritis (OA). Cells sense and engage with their mechanical microenvironment through interactions with the extracellular matrix. In the mandibular condylar cartilage, the pericellular microenvironment is composed of type VI collagen. NG2/CSPG4 is a transmembrane proteoglycan that binds with type VI collagen, and has been implicated in the cell stress response through mechanical loading-sensitive signaling networks including ERK 1/2. The objective of this study is to define the role of NG2/CSPG4 in the initiation and progression of TMJ OA and to determine if NG2/CSPG4 engages ERK 1/2 in a mechanical loading dependent manner. In vivo, we induced TMJ OA in control and NG2/CSPG4 knockout mice using a surgical destabilization approach. In control mice, NG2/CSPG4 is depleted during the early stages of TMJ OA and NG2/CSPG4 knockout mice have more severe cartilage degeneration, elevated expression of key OA proteases, and suppression of OA matrix synthesis genes. In vitro, we characterized the transcriptome and protein from control and NG2/CSPG4 knockout cells and found significant dysregulation of the ERK 1/2 signaling axis. To characterize the mechanobiological response of NG2/CSPG4, we applied mechanical loads on cell-agarose-collagen scaffolds using a compression bioreactor and illustrate that NG2/CSPG4 knockout cells fail to mechanically activate ERK 1/2 and are associated with changes in the expression of the same key OA biomarkers measured in vivo. Together, these findings implicate NG2/CSPG4 in the mechanical homeostasis of TMJ cartilage and in the progression of degenerative arthropathies including OA.

2022-09-24 | GSE214077 | GEO

BACH2 regulates T cell lineage states to enhance CAR T cell function [Cut & Run]

Project description:Nearly all chimeric antigen receptors (CARs) signal in the absence of antigen, referred to as “tonic signaling”. Tonic signaling of CARs containing the CD28 costimulatory domain has been shown to driveT cell exhaustion; in contrast, we found that tonic signaling of 41BB-containing CARs enhances T cell function. Using a panel of CARs targeting CD22, we identified that tonic 41BB signaling activatesBACH2, a transcriptional regulator that directs stem and memory programs. Overexpression of BACH2 prevented tonic CD28-driven exhaustion but locked CAR T cells in quiescent states. To overcome this, we linked BACH2 to a degradation domain and found that tuning BACH2 expression enhanced long-term efficacy of exhaustion-prone CAR T cells targeting liquid and solid tumors. Through interrogation of CAR products, we also found an association between BACH2 activity and clinical outcomes in patients with leukemia. These data identify a central role for BACH2 in regulating CAR T cell efficacy.

2025-12-08 | GSE312367 | GEO

BACH2 regulates T cell lineage states to enhance CAR T cell function [ATAC-seq]

2025-12-08 | GSE312384 | GEO

Transient “rest” induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells Mediate Enhanced Antitumor Activity [ATAC-seq]

Project description:T cell exhaustion limits immune responses against cancer and is a major cause of resistance to CAR-T cell therapeutics. Using a model wherein tonic CAR signaling induces hallmark features of exhaustion, we employed a drug-regulatable CAR to test the impact of transient cessation of receptor signaling (i.e. “rest”) on the development and maintenance of exhaustion. Induction of rest in exhausting or already-exhausted CAR-T cells resulted in acquisition of a memory-like phenotype, improved anti-tumor functionality, and wholescale transcriptional and epigenetic reprogramming. Similar results were achieved with the Src kinase inhibitor dasatinib, which reversibly suppresses CAR signaling. The degree of functional reinvigoration was proportional to the duration of rest and was associated with expression of transcription factors TCF1 and LEF1. This work demonstrates that transient cessation of CAR-T cell signaling can enhance anti-tumor potency by preventing or reversing exhaustion and challenges the paradigm that exhaustion is an epigenetically fixed state.

2021-01-16 | GSE164946 | GEO

Transient “rest” induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells Mediate Enhanced Antitumor Activity [RNA-seq]

2021-01-16 | GSE164949 | GEO

Transient “rest” induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells Mediate Enhanced Antitumor Activity [ATAC-seq, ChIP-seq]

2021-01-16 | GSE164947 | GEO